New appointment at Tris Pharma
This article was originally published in Scrip
Tris Pharma (US), a speciality pharmaceutical company focused on the development of drug delivery technologies, has appointed Peter Ciano vice-president of corporate development. He has been working for Tris as a business development consultant for more than eighteen months, and will now lead and manage the company's commercial activities for its brand side of the business.
You may also be interested in...
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
The EU’s upcoming pharma strategy offers an important opportunity for change, according to Medicines for Europe. The off-patent industry body has set out five key issues that should be priorities for the EU Commission.